Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabinoids:

Cannabinoids in late-onset Alzheimer's disease. Ahmed A et al. Clin Pharmacol Ther. (2015)

Cannabinoids in the Treatment of Epilepsy. Friedman D et al. N Engl J Med. (2015)

Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Castaneto MS et al. Drug Alcohol Depend. (2014)

Search results

Items: 1 to 20 of 15426

1.

Cannabinoids, the Heart of the Matter.

Alfulaij N, Meiners F, Michalek J, Small-Howard AL, Turner HC, Stokes AJ.

J Am Heart Assoc. 2018 Jul 13;7(14). pii: e009099. doi: 10.1161/JAHA.118.009099. Review. No abstract available.

PMID:
30006489
2.

Evidence for THC versus CBD in cannabinoids.

Perry D, Ton J, Allan GM.

Can Fam Physician. 2018 Jul;64(7):519. No abstract available.

PMID:
30002029
3.

The Pharmacokinetics and the Pharmacodynamics of Cannabinoids.

Lucas CJ, Galettis P, Schneider J.

Br J Clin Pharmacol. 2018 Jul 12. doi: 10.1111/bcp.13710. [Epub ahead of print] Review.

PMID:
30001569
4.

Screening, quantification and confirmation of synthetic cannabinoid metabolites in urine by UHPLC-QTOF-MS.

Gundersen POM, Spigset O, Josefsson M.

Drug Test Anal. 2018 Jul 11. doi: 10.1002/dta.2464. [Epub ahead of print]

PMID:
29996011
5.

Identification of Synergistic Interaction Between Cannabis-Derived Compounds for Cytotoxic Activity in Colorectal Cancer Cell Lines and Colon Polyps That Induces Apoptosis-Related Cell Death and Distinct Gene Expression.

Nallathambi R, Mazuz M, Namdar D, Shik M, Namintzer D, Vinayaka AC, Ion A, Faigenboim A, Nasser A, Laish I, Konikoff FM, Koltai H.

Cannabis Cannabinoid Res. 2018 Jun 1;3(1):120-135. doi: 10.1089/can.2018.0010. eCollection 2018.

6.

Developmental and behavioral effects in neonatal and adult mice following prenatal activation of endocannabinoid receptors by capsaicin.

Perchuk A, Bierbower SM, Canseco-Alba A, Mora Z, Tyrell L, Joshi N, Schanz N, Gould GG, Onaivi ES.

Acta Pharmacol Sin. 2018 Jul 10. doi: 10.1038/s41401-018-0073-z. [Epub ahead of print]

PMID:
29991708
7.

Clinical and analytical experience of the National Poison Control Centre with synthetic cannabinoids.

Vučinić S, Kilibarda V, Đorđević S, Đorđević D, Perković-Vukčević N, Vuković-Ercegović G, Antonijević B, Ćurčić M, Antonijević E, Brajković G.

Arh Hig Rada Toksikol. 2018 Jun 1;69(2):178-185. doi: 10.2478/aiht-2018-69-3096.

PMID:
29990297
8.

A case of synthetic cannabinoid poisoning in Croatia.

Sutlović D, Prkačin I, Vaiano F, Bertol E, Bratinčević MV, Definis-Gojanović M.

Arh Hig Rada Toksikol. 2018 Jun 1;69(2):186-190. doi: 10.2478/aiht-2018-69-3100.

PMID:
29990295
9.

Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015).

Kasper AM, Ridpath AD, Gerona RR, Cox R, Galli R, Kyle PB, Parker C, Arnold JK, Chatham-Stephens K, Morrison MA, Olayinka O, Preacely N, Kieszak SM, Martin C, Schier JG, Wolkin A, Byers P, Dobbs T.

Clin Toxicol (Phila). 2018 Jul 10:1-9. doi: 10.1080/15563650.2018.1485927. [Epub ahead of print]

PMID:
29989463
10.

Chronic, intermittent treatment with a cannabinoid receptor agonist impairs recognition memory and brain network functional connectivity.

Mouro FM, Ribeiro JA, Sebastião AM, Dawson N.

J Neurochem. 2018 Jul 10. doi: 10.1111/jnc.14549. [Epub ahead of print]

PMID:
29989183
11.

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study: a phase 1 dosage escalation study.

Reithmeier D, Tang-Wai R, Seifert B, Lyon AW, Alcorn J, Acton B, Corley S, Prosser-Loose E, Mousseau DD, Lim HJ, Tellez-Zenteno J, Huh L, Leung E, Carmant L, Huntsman RJ.

BMC Pediatr. 2018 Jul 7;18(1):221. doi: 10.1186/s12887-018-1191-y.

12.

Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation.

Mulpuri Y, Marty VN, Munier JJ, Mackie K, Schmidt BL, Seltzman HH, Spigelman I.

Neuropharmacology. 2018 Jul 5;139:85-97. doi: 10.1016/j.neuropharm.2018.07.002. [Epub ahead of print]

PMID:
29981335
13.

Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study.

Pellesi L, Licata M, Verri P, Vandelli D, Palazzoli F, Marchesi F, Cainazzo MM, Pini LA, Guerzoni S.

Eur J Clin Pharmacol. 2018 Jul 6. doi: 10.1007/s00228-018-2516-3. [Epub ahead of print]

PMID:
29980818
14.

An Assessment of the Genotoxicity and Subchronic Toxicity of a Supercritical Fluid Extract of the Aerial Parts of Hemp.

Marx TK, Reddeman R, Clewell AE, Endres JR, Béres E, Vértesi A, Glávits R, Hirka G, Szakonyiné IP.

J Toxicol. 2018 Jun 7;2018:8143582. doi: 10.1155/2018/8143582. eCollection 2018.

15.

Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community.

Suraev A, Lintzeris N, Stuart J, Kevin RC, Blackburn R, Richards E, Arnold JC, Ireland C, Todd L, Allsop DJ, McGregor IS.

Sci Rep. 2018 Jul 5;8(1):10154. doi: 10.1038/s41598-018-28127-0.

16.

Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study.

Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, Nielsen S, Cohen M, Chan G, Mattick RP, Blyth F, Shanahan M, Dobbins T, Farrell M, Degenhardt L.

Lancet Public Health. 2018 Jul;3(7):e341-e350. doi: 10.1016/S2468-2667(18)30110-5.

17.

The reasons for use of cannabinoids and stimulants in patients with schizophrenia.

Simonienko K, Wygnał N, Cwalina U, Kwiatkowski M, Szulc A, Waszkiewicz N.

Psychiatr Pol. 2018 Apr 30;52(2):261-273. doi: 10.12740/PP/68472. Epub 2018 Apr 30. English, Polish.

18.

Anti-Proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells.

Capozzi A, Mattei V, Martellucci S, Manganelli V, Saccomanni G, Garofalo T, Sorice M, Manera C, Misasi R.

Int J Mol Sci. 2018 Jul 4;19(7). pii: E1958. doi: 10.3390/ijms19071958.

19.

Clinical issues in cannabis use.

Bonomo Y, Souza JD, Jackson A, Crippa JAS, Solowij N.

Br J Clin Pharmacol. 2018 Jul 2. doi: 10.1111/bcp.13703. [Epub ahead of print] Review. No abstract available.

PMID:
29968386
20.

Marijuana matters: reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research.

Sagar KA, Gruber SA.

Int Rev Psychiatry. 2018 Jul 3:1-17. doi: 10.1080/09540261.2018.1460334. [Epub ahead of print]

PMID:
29966459

Supplemental Content

Loading ...
Support Center